Baxter provides update on heparin reactions

February 11, 2008 — /PRNewswire/ — DEERFIELD, IL — Baxter Healthcare Corporation is providing an update to its January 2008 heparin sodium injection 1,000 units/ml 10 and 30-ml multi-dose vial voluntary recall of nine lots, which the company initiated as a precautionary measure due to an increase in reports of adverse reactions that may be associated with the drug. Since the recall, Baxter has received reports of similar adverse reactions occurring in other lots of 1,000 units/ml, 10 and 30-ml multi-dose vials; 5,000 units/ml and 10,000 units/ml multi-dose vials; and 5,000 units/ml single-dose vials when single doses were combined to create a larger bolus dose.

Nearly all reported adverse reactions have occurred in three specific areas of product use


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.